摘要
目的:探讨吡拉西坦联合尼莫地平治疗急性原发性脑出血的临床疗效。方法:回顾性分析2018年2月~2019年6月于本院接受治疗的急性原发性脑出血患者85例的临床资料,根据药物治疗方案的不同进行分组,分别为对照组(常规治疗+尼莫地平,42例)与观察组(常规治疗+尼莫地平+吡拉西坦,43例)。两组均连续治疗2周,观察两组入选者治疗前后血肿体积及神经功能,并对比两组入选者治疗前后细胞因子水平、脑部血流参数,同时记录两组入选者治疗期间不良反应发生情况。结果:治疗后,两组入选者血肿体积均小于治疗前,美国国立卫生研究院卒中量表(NIHSS)评分均低于治疗前;与对照组相比,观察组血肿体积更小,NIHSS评分更低,具有统计学差异(P <0.05);治疗后,两组入选者神经元特异性烯醇化酶(NSE)、单核细胞趋化蛋白-1(MCP-1)水平均较治疗前降低,脑源性神经营养因子(BDNF)水平较治疗前升高,且观察组NSE、MCP-1水平更低,BNDF水平更高,具有统计学差异(P <0.05);治疗后,两组入选者平均血流速度(V_m)、搏动指数(PI)值均高于治疗前,阻力指数(RI)值均低于治疗前,且与对照组相比,观察组V_m和PI值更高、RI值更低,具有统计学差异(P <0.05);观察组不良反应发生率(13.95%)与对照组(9.52%)相比,无统计学差异(P> 0.05)。结论:吡拉西坦联合尼莫地平治疗急性原发性脑出血患者,利于缩小血肿体积、促进神经功能恢复,还可改善脑部血流动力学参数,且安全性较高。
Objective:To investigate the clinical efficacy of piracetam combined with nimodipine in treatment of primary intracerebral hemorrhage in acute stage.Methods:The clinical data of patients(85 cases)with primary intracerebral hemorrhage in acute stage treated in our hospital from February 2018 to June 2019 were retrospectively analyzed.According to different drug treatment regimens,patients were divided into control group(routine treatment and nimodipine,42 cases)and observation group(routine treatment,nimodipine and piracetam,43 cases).Both groups were treated for 2 consecutive weeks.The hematoma volume,nerve function,cytokine levels and cerebral blood flow parameters before and after treatment in the two groups were observed and compared.The incidence of adverse reactions in the two groups during treatment was recorded.Results:After treatment,the hematoma volume of two groups was smaller than that of before treatment.The scores of the National Institutes of Health Stroke Scale(NIHSS)were lower than those of before treatment;Compared with control group,the hematoma volume of observation group was smaller,and the NIHSS score was lower(P<0.05);After treatment,the levels of neuron specific enolase(NSE)and monocyte chemoattractant protein-1(MCP-1)in both groups were lower than before treatment,while the level of brain-derived neurotrophic factor(BDNF)was higher than before treatment.The levels of NSE and MCP-1 were lower and BDNF was higher in the observation group than in the control group(P<0.05);After treatment,the mean flow velocity(V m)and pulsatility index(PI)in two groups were higher than before treatment,and the resistance index(RI)was lower.Compared with control group,the V m and PI were higher,and the RI was lower in observation group(P<0.05);There was no statistical difference in the incidence of adverse reactions between observation group(13.95%)and control group(9.52%,P>0.05).Conclusion:Piracetam combined with nimodipine in treatment of patients with primary intracerebral hemorrhage in acute stage is benef
作者
崔青丽
CUI Qing-li(Hemodialysis Room,Affiliated Hospital of Xinyang Vocational and Technical College of Xinyang City,Henan Province,Xinyang 464000,China)
出处
《中国合理用药探索》
CAS
2021年第1期78-81,共4页
Chinese Journal of Rational Drug Use
